Search Results

You are looking at 1 - 10 of 1,132 items for :

  • Refine by Access: All x
Clear All
Full access

Does Use of the Adjuvant! Model Influence Use of Adjuvant Therapy Through Better Risk Communication?

Jeffrey K. Belkora, David W. Hutton, Dan H. Moore, and Laura A. Siminoff

P atients with breast cancer who are at relatively low risk for recurrence or mortality after local therapy (surgery with or without radiation) face a “grey zone” decision about whether to undergo adjuvant therapy. 1 The choice of therapy

Full access

Where Are We With Adjuvant Therapy of Stage III and IV Melanoma in 2009?

Leslie A. Fecher and Keith T. Flaherty

Dr. Fecher has disclosed that she is a site Principal Investigator for ECOG 1697 and for an adjuvant vaccine trial. Dr. Flaherty has disclosed that he is on the advisory board for Schering-Plough Corporation. References 1

Full access

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

NCCN Adjuvant Therapy for Breast Cancer Task Force Members *Robert W. Carlson, MD / Chair#†  ¶¶ Stanford Hospital and Clinics Donald A. Berry, PhD††  The University of Texas M. D. Anderson Cancer Center *Elizabeth Brown, MD  National Comprehensive

Full access

Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?

Rosalyn A. Juergens and Julie R. Brahmer

Vanecko RM Fry WA . Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure . Ann Thorac Surg 1981 ; 32 : 23 – 27 . 6. Arriagada R Bergman B Dunant A . Cisplatin-based adjuvant chemotherapy in patients

Full access

Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis

Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama, and Manisha Palta

resection and consideration of adjuvant chemotherapy (AC) based on patient and tumor characteristics. The role of AC in colon cancer is supported by the results of NSABP C01, 1 a pooled analysis, 2 and the MOSAIC trial 3 showing improvement in disease

Full access

Counterpoint: Adjuvant Therapy in Stage II Colon Cancer: Pain Not Justified by the Gain

Katherine Van Loon and Alan P. Venook

Adjuvant therapy for colon cancer evolved in an additive fashion. In the 1980s, 5-fluorouracil (5-FU) administered as a daily bolus regimen made the first positive impact of any therapy on colon cancer survival. 1 The ensuing decade of research

Full access

Salvage or Adjuvant Radiation Therapy: Counseling Patients on the Benefits

Matthew E. Nielsen, Bruce J. Trock, and Patrick C. Walsh

Guidelines in Oncology: Prostate Cancer states “new evidence supports offering adjuvant/salvage RT in all men with adverse pathologic features or detectable PSA” 3 (to view the most recent version of these guidelines, visit the NCCN Web site at www

Full access

Point: Treating Stage II Colon Cancer: The Quest for Personalized Adjuvant Care

Maxwell T. Vergo and Al B. Benson III

compared with those with stage II (T4b–a,N0), with 5-year survivals of 83% to 91% versus 58% to 79%, respectively, 5 and yet are offered adjuvant chemotherapy. Evidence shows that stage II and III disease have very similar gene expression profiles and

Full access

Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma

Anthony J. Olszanski

Patients with stage III melanoma are at high risk for disease recurrence, but adjuvant therapy—including targeted therapy and immunotherapy—may prevent or delay relapse, according to Anthony J. Olszanski, MD, RPh, Associate Professor and Vice Chair

Full access

Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center

Jeffrey M. Martin, Tianyu Li, Matthew E. Johnson, Colin T. Murphy, Alan G. Howald, Marc C. Smaldone, Alexander Kutikov, David Y.T. Chen, Rosalia Viterbo, Richard E. Greenberg, Robert G. Uzzo, and Eric M. Horwitz

undergoing prostatectomy will have high-risk pathologic features, such as extracapsular extension, seminal vesicle invasion, or positive surgical margins. 3 , 4 Three randomized trials have shown a benefit for treating these men with adjuvant radiation to